Translational Value of Proteinuria and
eGFR as Surrogate Endpoints for Patients
with IgA Nephropathy
Learn how endpoints from clinical trials inform patient
care
Epidemiologic studies have demonstrated a significant association between changes in proteinuria and kidney outcomes in patients with IgA nephropathy.1 In this discussion, Dr. Richard Lafayette explains how the validation of proteinuria as a surrogate endpoint led to the acceleration of clinical trials for new treatments in IgA nephropathy, while eGFR and eGFR slope remain important clinical outcomes.
00:13:12
References: 1. Thompson A, Carroll K, A. Inker L, Floege J, Perkovic V, Boyer-Suavet S, W. Major R, I. Schimpf J, Barratt J, Cattran DC, S. Gillespie B, Kausz A, W. Mercer A, Reich HN, H. Rovin B, West M, Nachman PH (2019) Proteinuria Reduction as a Surrogate End Point in Trials of IgA Nephropathy. CJASN 14(3):469–481. https://doi.org/10.2215/CJN.08600718